Evidence map›Paper›PMID 35276442›Full record

ArticleRedox biology2022

Biochemical and structural characterizations of thioredoxin reductase selenoproteins of the parasitic filarial nematodes Brugia malayi and Onchocerca volvulus.

Francesca Fata, Radosveta Gencheva, Qing Cheng, Rachel Lullo, Matteo Ardini, Ilaria Silvestri, Federica Gabriele, Rodolfo Ippoliti, Christina A Bulman, Judy A Sakanari and 3 more

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Structural and Mechanistic Characterization ofInternational journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Evaluation of Auranofin Loading within Ferritin Nanocages.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

Francesca FataDept. of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy.
Radosveta GenchevaDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden.
Qing ChengDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden.
Rachel LulloDept. of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL, USA.
Matteo ArdiniDept. of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy.
Ilaria SilvestriDept. of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy.
Federica GabrieleDept. of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy.
Rodolfo IppolitiDept. of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy.
Christina A BulmanDept. of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Judy A SakanariDept. of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
David L WilliamsDept. of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, IL, USA.
Elias S J ArnérDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, 17177, Sweden; Department of Selenoprotein Research, National Institute of Oncology, 1122, Budapest, Hungary.
Francesco AngelucciDept. of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy. Electronic address: francesco.angelucci@univaq.it.
University of L'Aquila · ITKarolinska Institutet · SERush University Medical Center · USUniversity of California, San Francisco · US

Funding

Identification of preclinical drug candidates for the treatment of schistosomiasisR33AI127635 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI PETUKHOV, PAVEL A, THATCHER, GREGORY R. J · 2019 to 2021
$1.3M
NIAID NIH HHS HHSN272201200025CNIAID NIH HHS R33 AI127635
6 · The paper itself

Abstract

Enzymes in the thiol redox systems of microbial pathogens are promising targets for drug development. In this study we characterized the thioredoxin reductase (TrxR) selenoproteins from Brugia malayi and Onchocerca volvulus, filarial nematode parasites and causative agents of lymphatic filariasis and onchocerciasis, respectively. The two filarial enzymes showed similar turnover numbers and affinities for different thioredoxin (Trx) proteins, but with a clear preference for the autologous Trx. Human TrxR1 (hTrxR1) had a high and similar specific activity versus the human and filarial Trxs, suggesting that, in vivo, hTrxR1 could possibly be the reducing agent of parasite Trxs once they are released into the host. Both filarial TrxRs were efficiently inhibited by auranofin and by a recently described inhibitor of human TrxR1 (TRi-1), but not as efficiently by the alternative compound TRi-2. The enzyme from B. malayi was structurally characterized also in complex with NADPH and auranofin, producing the first crystallographic structure of a nematode TrxR. The protein represents an unusual fusion of a mammalian-type TrxR protein architecture with an N-terminal glutaredoxin-like (Grx) domain lacking typical Grx motifs. Unlike thioredoxin glutathione reductases (TGRs) found in platyhelminths and mammals, which are also Grx-TrxR domain fusion proteins, the TrxRs from the filarial nematodes lacked glutathione disulfide reductase and Grx activities. The structural determinations revealed that the Grx domain of TrxR from B. malayi contains a cysteine (C22), conserved in TrxRs from clade IIIc nematodes, that directly interacts with the C-terminal cysteine-selenocysteine motif of the homo-dimeric subunit. Interestingly, despite this finding we found that altering C22 by mutation to serine did not affect enzyme catalysis. Thus, although the function of the Grx domain in these filarial TrxRs remains to be determined, the results obtained provide insights on key properties of this important family of selenoprotein flavoenzymes that are potential drug targets for treatment of filariasis.

Indexed as

Brugia malayiOnchocerca volvulusParasitesAnimalsAuranofinCysteineHumansMammalsOxidation-ReductionSelenoproteinsThioredoxin-Disulfide ReductaseThioredoxinsAuranofinCysteineSelenoproteinsThioredoxin-Disulfide ReductaseThioredoxinsAuranofinGlutaredoxinSelenocysteineThioredoxin reductaseThioredoxin reductase inhibitorX-ray crystallography

Identifiers

PMID35276442
PMCPMC8914392
OpenAlexW4220765190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.